{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:56:59Z","timestamp":1787162219762,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T00:00:00Z","timestamp":1734393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaloncologyonline.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Oncology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clon.2024.103741","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:23:12Z","timestamp":1734567792000},"page":"103741","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Effects of Radiotherapy Alone Versus Concomitant Radiotherapy With Temozolomide Chemotherapy on the Outcome of IDH-wildtype Glioblastoma Patients"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8979-3849","authenticated-orcid":false,"given":"M.","family":"Kurdi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6528-9592","authenticated-orcid":false,"given":"A.","family":"Alkhotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Alsinani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Alkhayyat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7894-2490","authenticated-orcid":false,"given":"Y.","family":"Katib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Jastaniah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Sabbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0473-4920","authenticated-orcid":false,"given":"N.S.","family":"Butt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.A.","family":"Toonsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Alharbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-7912","authenticated-orcid":false,"given":"S.","family":"Baeesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clon.2024.103741_bib1","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of Tumors of the Central Nervous System: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"7","key":"10.1016\/j.clon.2024.103741_bib2","doi-asserted-by":"crossref","first-page":"567","DOI":"10.5306\/wjco.v13.i7.567","article-title":"Simple approach for the histomolecular diagnosis of central nervous system gliomas based on 2021 World Health Organization Classification","volume":"13","author":"Kurdi","year":"2022","journal-title":"World J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clon.2024.103741_bib3","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1200\/JCO.2002.20.5.1375","article-title":"Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide","volume":"20","author":"Stupp","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.clon.2024.103741_bib4","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","article-title":"Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery","volume":"303","author":"Walker","year":"1980","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.clon.2024.103741_bib5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0167-8140(02)00078-6","article-title":"Cancer Care Ontario Practice Guidelines Initiative Neuro-Oncology Disease Site Group. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review","volume":"64","author":"Laperriere","year":"2002","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.clon.2024.103741_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/1097-0142(19830915)52:6<997::AID-CNCR2820520612>3.0.CO;2-2","article-title":"Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study","volume":"52","author":"Chang","year":"1983","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clon.2024.103741_bib7","first-page":"121","article-title":"Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma","volume":"67","author":"Green","year":"1983","journal-title":"Cancer Treat Rep"},{"issue":"12","key":"10.1016\/j.clon.2024.103741_bib8","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.1998.16.12.3851","article-title":"DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma","volume":"16","author":"Friedman","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.clon.2024.103741_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.clon.2024.103741_bib10","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.clon.2024.103741_bib11","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.clon.2024.103741_bib12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S1470-2045(21)00090-5","article-title":"Adjuvant and concurrent temozolomide for 1p\/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study","volume":"22","author":"van den Bent","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clon.2024.103741_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/pore.2021.1609778","article-title":"The Impact of IDH1 Mutation and MGMT Promoter Methylation on Recurrence-Free Interval in Glioblastoma Patients Treated with Radiotherapy and Chemotherapeutic Agents","volume":"27","author":"Kurdi","year":"2021","journal-title":"Pathol Oncol Res"},{"issue":"2","key":"10.1016\/j.clon.2024.103741_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188616","article-title":"Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance","volume":"1876","author":"Tomar","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"10.1016\/j.clon.2024.103741_bib15","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"6","key":"10.1016\/j.clon.2024.103741_bib16","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1215\/15228517-2008-058","article-title":"A\u00a0novel tool to analyze MRI recurrence patterns in glioblastoma","volume":"10","author":"Wick","year":"2008","journal-title":"Neuro Oncol"},{"issue":"33","key":"10.1016\/j.clon.2024.103741_bib17","first-page":"58","article-title":"Factors affecting Survival in Glioblastoma: A 10-year Single-Center Experience from Saudi Arabia","volume":"1","author":"Azab","year":"2020","journal-title":"Gulf J Oncolog"},{"key":"10.1016\/j.clon.2024.103741_bib18","doi-asserted-by":"crossref","DOI":"10.4178\/epih.e2021037","article-title":"Epidemiological distribution of primary central nervous system tumors in the Western Province of Saudi Arabia: a local registry from neuroscience-affiliated centers","volume":"43","author":"Kurdi","year":"2021","journal-title":"Epidemiol Health"},{"issue":"9","key":"10.1016\/j.clon.2024.103741_bib19","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/85.9.704","article-title":"Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials","volume":"85","author":"Curran","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.clon.2024.103741_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.clon.2024.103741_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074242","article-title":"Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the elderly: a meta-analysis","volume":"8","author":"Yin","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.clon.2024.103741_bib22","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13014-019-1389-7","article-title":"Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged \u2265 75 years","volume":"14","author":"Ohno","year":"2019","journal-title":"Radiat Oncol"},{"issue":"44","key":"10.1016\/j.clon.2024.103741_bib23","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008444","article-title":"A\u00a0comparison between oral chemotherapy combined with radiotherapy and radiotherapy for newly diagnosed glioblastoma: A systematic review and meta-analysis","volume":"96","author":"Wang","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.clon.2024.103741_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2021.12.009","article-title":"Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II\/III gliomas: A prospective randomized study","volume":"167","author":"Qiu","year":"2022","journal-title":"Radiother Oncol"},{"issue":"12","key":"10.1016\/j.clon.2024.103741_bib25","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1158\/1078-0432.CCR-21-4283","article-title":"Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial","volume":"28","author":"Tesileanu","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524005454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0936655524005454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:08:30Z","timestamp":1748452110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0936655524005454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":25,"alternative-id":["S0936655524005454"],"URL":"https:\/\/doi.org\/10.1016\/j.clon.2024.103741","relation":{},"ISSN":["0936-6555"],"issn-type":[{"value":"0936-6555","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Radiotherapy Alone Versus Concomitant Radiotherapy With Temozolomide Chemotherapy on the Outcome of IDH-wildtype Glioblastoma Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clon.2024.103741","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.","name":"copyright","label":"Copyright"}],"article-number":"103741"}}